NASDAQ:URGN - UroGen Pharma Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$61.47 -0.42 (-0.68 %)
(As of 05/24/2018 02:23 AM ET)
Previous Close$61.89
Today's Range$61.06 - $62.78
52-Week Range$14.52 - $69.57
Volume59,200 shs
Average Volume134,958 shs
Market Capitalization$864.41 million
P/E Ratio-28.86
Dividend YieldN/A
BetaN/A

About UroGen Pharma (NASDAQ:URGN)

UroGen Pharma logoUroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. Its lead product candidates, MitoGel and VesiGel are proprietary formulations of the chemotherapy drug Mitomycin C, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy. The company is developing its product candidates as chemoablation agents, which are designed to remove tumors by non-surgical means, to treat various forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma, and low-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Ra'anana, Israel.

Receive URGN News and Ratings via Email

Sign-up to receive the latest news and ratings for URGN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:URGN
CUSIPN/A
Phone972-9770-7601

Debt

Debt-to-Equity RatioN/A
Current Ratio23.28
Quick Ratio23.22

Price-To-Earnings

Trailing P/E Ratio-28.86
Forward P/E Ratio-17.56
P/E GrowthN/A

Sales & Book Value

Annual Sales$8.16 million
Price / Sales103.58
Cash FlowN/A
Price / CashN/A
Book Value$9.01 per share
Price / Book6.82

Profitability

EPS (Most Recent Fiscal Year)($2.14)
Net Income$-20,000,000.00
Net MarginsN/A
Return on Equity-35.54%
Return on Assets-33.35%

Miscellaneous

Employees33
Outstanding Shares13,750,000

UroGen Pharma (NASDAQ:URGN) Frequently Asked Questions

What is UroGen Pharma's stock symbol?

UroGen Pharma trades on the NASDAQ under the ticker symbol "URGN."

How were UroGen Pharma's earnings last quarter?

UroGen Pharma (NASDAQ:URGN) announced its earnings results on Tuesday, May, 15th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.73) by $0.15. The firm earned $0.48 million during the quarter. View UroGen Pharma's Earnings History.

When is UroGen Pharma's next earnings date?

UroGen Pharma is scheduled to release their next quarterly earnings announcement on Monday, August, 13th 2018. View Earnings Estimates for UroGen Pharma.

What price target have analysts set for URGN?

7 analysts have issued 1 year price objectives for UroGen Pharma's shares. Their predictions range from $25.00 to $75.00. On average, they anticipate UroGen Pharma's share price to reach $50.60 in the next twelve months. View Analyst Ratings for UroGen Pharma.

What are Wall Street analysts saying about UroGen Pharma stock?

Here are some recent quotes from research analysts about UroGen Pharma stock:
  • 1. According to Zacks Investment Research, "UroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with a focus on uro-oncology. The company's product candidates include MitoGel and VesiGel which are in clinical trial stage. Its platform technologies include: RTGel and Immunotherapy. UroGen Pharma Ltd. is based in Ra'anana, Israel. " (5/15/2018)
  • 2. Cowen Inc analysts commented, "URGN presented updates for MitoGel’s Phase 3 OLYMPUS trial (topline data in 2Q18)." (11/15/2017)

Who are some of UroGen Pharma's key competitors?

Who are UroGen Pharma's key executives?

UroGen Pharma's management team includes the folowing people:
  • Mr. Ron Bentsur, CEO & Director (Age 52)
  • Mr. Gary S. Titus, CFO & Principal Accounting Officer (Age 58)
  • Mr. Stephen Mullennix, Chief Operating Officer
  • Ms. Catherine Bechtold, Director of Corp. Communications and Investor Relations
  • Ms. Christine Cassiano, Corp. Affairs Officer

When did UroGen Pharma IPO?

(URGN) raised $46 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 3,500,000 shares at $12.00-$14.00 per share. Jefferies and Cowen and Company served as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers.

Has UroGen Pharma been receiving favorable news coverage?

Media coverage about URGN stock has trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm rates the sentiment of press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. UroGen Pharma earned a media sentiment score of 0.21 on Accern's scale. They also assigned news coverage about the company an impact score of 45.57 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

Who are UroGen Pharma's major shareholders?

UroGen Pharma's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Clal Insurance Enterprises Holdings Ltd (2.06%), Millennium Management LLC (1.16%), Citadel Advisors LLC (0.59%), Lyon Street Capital LLC (0.24%), Barclays PLC (0.18%) and Alps Advisors Inc. (0.15%). View Institutional Ownership Trends for UroGen Pharma.

Which major investors are selling UroGen Pharma stock?

URGN stock was sold by a variety of institutional investors in the last quarter, including Lyon Street Capital LLC and JPMorgan Chase & Co.. View Insider Buying and Selling for UroGen Pharma.

Which major investors are buying UroGen Pharma stock?

URGN stock was acquired by a variety of institutional investors in the last quarter, including Clal Insurance Enterprises Holdings Ltd, Millennium Management LLC, Citadel Advisors LLC, Barclays PLC, Alps Advisors Inc., DAFNA Capital Management LLC, Quantbot Technologies LP and ETF Managers Group LLC. View Insider Buying and Selling for UroGen Pharma.

How do I buy shares of UroGen Pharma?

Shares of URGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is UroGen Pharma's stock price today?

One share of URGN stock can currently be purchased for approximately $61.47.

How big of a company is UroGen Pharma?

UroGen Pharma has a market capitalization of $864.41 million and generates $8.16 million in revenue each year. The company earns $-20,000,000.00 in net income (profit) each year or ($2.14) on an earnings per share basis. UroGen Pharma employs 33 workers across the globe.

How can I contact UroGen Pharma?

UroGen Pharma's mailing address is 9 HaTaasiya St, Raanana L3, 4365007. The company can be reached via phone at 972-9770-7601 or via email at [email protected]


MarketBeat Community Rating for UroGen Pharma (URGN)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  100 (Vote Outperform)
Underperform Votes:  103 (Vote Underperform)
Total Votes:  203
MarketBeat's community ratings are surveys of what our community members think about UroGen Pharma and other stocks. Vote "Outperform" if you believe URGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe URGN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

UroGen Pharma (NASDAQ:URGN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
7 Wall Street analysts have issued ratings and price targets for UroGen Pharma in the last 12 months. Their average twelve-month price target is $50.60, suggesting that the stock has a possible downside of 17.68%. The high price target for URGN is $75.00 and the low price target for URGN is $25.00. There are currently 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.002.712.67
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $50.60$50.60$42.80$41.00
Price Target Upside: 17.68% downside15.38% downside15.02% upside1.35% downside

UroGen Pharma (NASDAQ:URGN) Consensus Price Target History

Price Target History for UroGen Pharma (NASDAQ:URGN)

UroGen Pharma (NASDAQ:URGN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/22/2018OppenheimerSet Price TargetBuy$75.00MediumView Rating Details
5/15/2018CowenReiterated RatingBuyHighView Rating Details
4/4/2018UBSUpgradeMarket Perform ➝ OutperformHighView Rating Details
4/4/2018Raymond JamesUpgradeMarket Perform ➝ OutperformHighView Rating Details
3/19/2018Jefferies GroupReiterated RatingBuyLowView Rating Details
3/16/2018Ladenburg ThalmannReiterated RatingBuy ➝ Buy$65.00HighView Rating Details
11/15/2017CIBCReiterated RatingOutperform ➝ Outperform$32.00 ➝ $51.00N/AView Rating Details
(Data available from 5/24/2016 forward)

Earnings

UroGen Pharma (NASDAQ:URGN) Earnings History and Estimates Chart

Earnings by Quarter for UroGen Pharma (NASDAQ:URGN)

UroGen Pharma (NASDAQ:URGN) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20182($1.00)($0.90)($0.95)
Q3 20182($1.01)($0.99)($1.00)
Q4 20182($1.18)($1.03)($1.11)

UroGen Pharma (NASDAQ URGN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/13/2018        
5/15/20183/31/2018($0.73)($0.88)$0.48 millionViewN/AView Earnings Details
3/15/2018n/a($0.65)($0.74)$0.33 millionViewListenView Earnings Details
11/14/2017Q3 2017$0.08($0.02)$7.67 million$7.81 millionViewN/AView Earnings Details
8/14/2017Q2 2017($0.46)($0.70)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

UroGen Pharma (NASDAQ:URGN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

UroGen Pharma (NASDAQ URGN) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 67.39%
Insider Trading History for UroGen Pharma (NASDAQ:URGN)
Institutional Ownership by Quarter for UroGen Pharma (NASDAQ:URGN)

UroGen Pharma (NASDAQ URGN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/28/2017Proquest Investments Iv, L.P.Major ShareholderSell209,298$40.60$8,497,498.80View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

UroGen Pharma (NASDAQ URGN) News Headlines

Source:
DateHeadline
UroGen Pharma (URGN) Given a $75.00 Price Target by Oppenheimer AnalystsUroGen Pharma (URGN) Given a $75.00 Price Target by Oppenheimer Analysts
www.americanbankingnews.com - May 22 at 12:04 PM
Urogens MitoGel shows treatment effect in late-stage urothelial cancer studyUrogen's MitoGel shows treatment effect in late-stage urothelial cancer study
seekingalpha.com - May 22 at 9:18 AM
UroGen Pharma Announces Positive Interim Results from Pivotal Phase 3 OLYMPUS Trial of UGN-101 (MitoGel™) for Non-Surgical Treatment of Upper Tract Urothelial Cancer (UTUC)UroGen Pharma Announces Positive Interim Results from Pivotal Phase 3 OLYMPUS Trial of UGN-101 (MitoGel™) for Non-Surgical Treatment of Upper Tract Urothelial Cancer (UTUC)
finance.yahoo.com - May 21 at 4:25 PM
Zacks: Analysts Anticipate UroGen Pharma (URGN) Will Announce Earnings of -$0.93 Per ShareZacks: Analysts Anticipate UroGen Pharma (URGN) Will Announce Earnings of -$0.93 Per Share
www.americanbankingnews.com - May 19 at 11:15 PM
Jefferies Group Analysts Cut Earnings Estimates for UroGen Pharma (URGN)Jefferies Group Analysts Cut Earnings Estimates for UroGen Pharma (URGN)
www.americanbankingnews.com - May 18 at 7:30 AM
Research Analysts Offer Predictions for UroGen Pharmas Q2 2018 Earnings (URGN)Research Analysts Offer Predictions for UroGen Pharma's Q2 2018 Earnings (URGN)
www.americanbankingnews.com - May 18 at 7:30 AM
Oppenheimer Reiterates "$75.00" Price Target for UroGen Pharma (URGN)Oppenheimer Reiterates "$75.00" Price Target for UroGen Pharma (URGN)
www.americanbankingnews.com - May 16 at 3:23 PM
UroGen Pharma (URGN) Rating Reiterated by CowenUroGen Pharma (URGN) Rating Reiterated by Cowen
www.americanbankingnews.com - May 15 at 5:23 PM
UroGen Pharmas (URGN) CEO Ron Bentsur on Q1 2018 Results - Earnings Call TranscriptUroGen Pharma's (URGN) CEO Ron Bentsur on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 15 at 4:46 PM
UroGen Pharma (URGN) Upgraded at Zacks Investment ResearchUroGen Pharma (URGN) Upgraded at Zacks Investment Research
www.americanbankingnews.com - May 15 at 4:26 PM
UroGen Pharma (URGN) Releases Quarterly  Earnings Results, Misses Estimates By $0.15 EPSUroGen Pharma (URGN) Releases Quarterly Earnings Results, Misses Estimates By $0.15 EPS
www.americanbankingnews.com - May 15 at 11:59 AM
UroGen Pharma misses by $0.16UroGen Pharma misses by $0.16
seekingalpha.com - May 15 at 10:01 AM
Analysts Expect Breakeven For UroGen Pharma Ltd (NASDAQ:URGN)Analysts Expect Breakeven For UroGen Pharma Ltd (NASDAQ:URGN)
finance.yahoo.com - May 15 at 10:01 AM
UroGen Pharma Reports First Quarter 2018 Financial Results and Recent Corporate DevelopmentsUroGen Pharma Reports First Quarter 2018 Financial Results and Recent Corporate Developments
finance.yahoo.com - May 15 at 10:01 AM
UroGen Pharma (URGN) Scheduled to Post Earnings on TuesdayUroGen Pharma (URGN) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - May 10 at 1:00 PM
UroGen Pharma (URGN) Receives Average Recommendation of "Buy" from AnalystsUroGen Pharma (URGN) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - May 9 at 3:28 AM
UroGen Pharma (URGN) Cut to "Sell" at Zacks Investment ResearchUroGen Pharma (URGN) Cut to "Sell" at Zacks Investment Research
www.americanbankingnews.com - May 8 at 4:05 PM
UroGen Pharma to Report First Quarter 2018 Financial Results on Tuesday, May 15, 2018UroGen Pharma to Report First Quarter 2018 Financial Results on Tuesday, May 15, 2018
finance.yahoo.com - May 8 at 9:25 AM
UroGen Pharma (URGN) Raised to "Hold" at ValuEngineUroGen Pharma (URGN) Raised to "Hold" at ValuEngine
www.americanbankingnews.com - May 2 at 3:12 PM
 Brokerages Anticipate UroGen Pharma (URGN) to Post -$0.73 Earnings Per Share Brokerages Anticipate UroGen Pharma (URGN) to Post -$0.73 Earnings Per Share
www.americanbankingnews.com - May 2 at 11:13 AM
UroGen Pharma to Ring the Nasdaq Stock Market Opening BellUroGen Pharma to Ring the Nasdaq Stock Market Opening Bell
globenewswire.com - April 24 at 9:28 AM
-$0.73 Earnings Per Share Expected for Urogen Pharma Ltd (URGN) This Quarter-$0.73 Earnings Per Share Expected for Urogen Pharma Ltd (URGN) This Quarter
www.americanbankingnews.com - April 15 at 11:15 AM
Zacks Investment Research Upgrades Urogen Pharma (URGN) to BuyZacks Investment Research Upgrades Urogen Pharma (URGN) to Buy
www.americanbankingnews.com - April 14 at 10:05 AM
Urogen Pharma Ltd (URGN) Given Consensus Recommendation of "Buy" by BrokeragesUrogen Pharma Ltd (URGN) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 14 at 3:30 AM
Analyzing Urogen Pharma (URGN) and Its CompetitorsAnalyzing Urogen Pharma (URGN) and Its Competitors
www.americanbankingnews.com - April 13 at 5:21 PM
UroGen Pharma (URGN) Presents Data From Interim Analysis of Pivotal Phase 3 OLYMPUS Trial of UGN-101 for Non-Surgical Treatment of UTUCUroGen Pharma (URGN) Presents Data From Interim Analysis of Pivotal Phase 3 OLYMPUS Trial of UGN-101 for Non-Surgical Treatment of UTUC
www.streetinsider.com - April 4 at 5:06 PM
Today’s Research Reports on Stocks to Watch: UroGen Pharma and NovartisToday’s Research Reports on Stocks to Watch: UroGen Pharma and Novartis
finance.yahoo.com - April 4 at 5:06 PM
Urogen Pharma (URGN) Upgraded at UBSUrogen Pharma (URGN) Upgraded at UBS
www.americanbankingnews.com - April 4 at 12:49 PM
Urogen Pharma (URGN) Lifted to "Buy" at Raymond James FinancialUrogen Pharma (URGN) Lifted to "Buy" at Raymond James Financial
www.americanbankingnews.com - April 4 at 8:04 AM
Urogen Pharmas (URGN) Buy Rating Reiterated at OppenheimerUrogen Pharma's (URGN) Buy Rating Reiterated at Oppenheimer
www.americanbankingnews.com - April 3 at 10:40 AM
UroGen Pharma Announces Presentation of Results from Interim Analysis of Pivotal Phase 3 OLYMPUS Trial of UGN-101 (MitoGel™) for Non-Surgical Treatment of Upper Tract Urothelial Cancer (UTUC)UroGen Pharma Announces Presentation of Results from Interim Analysis of Pivotal Phase 3 OLYMPUS Trial of UGN-101 (MitoGel™) for Non-Surgical Treatment of Upper Tract Urothelial Cancer (UTUC)
finance.yahoo.com - April 3 at 9:49 AM
Urogen Pharma (URGN) & Its Rivals Critical AnalysisUrogen Pharma (URGN) & Its Rivals Critical Analysis
www.americanbankingnews.com - April 2 at 1:30 AM
-$0.75 EPS Expected for Urogen Pharma Ltd (URGN) This Quarter-$0.75 EPS Expected for Urogen Pharma Ltd (URGN) This Quarter
www.americanbankingnews.com - March 29 at 1:16 PM
Urogen Pharmas (URGN) "Buy" Rating Reaffirmed at OppenheimerUrogen Pharma's (URGN) "Buy" Rating Reaffirmed at Oppenheimer
www.americanbankingnews.com - March 22 at 4:05 PM
Urogen Pharma Ltd (URGN) Receives Consensus Rating of "Buy" from AnalystsUrogen Pharma Ltd (URGN) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - March 20 at 3:34 AM
Urogen Pharma (URGN) Given Buy Rating at Jefferies GroupUrogen Pharma (URGN) Given Buy Rating at Jefferies Group
www.americanbankingnews.com - March 19 at 5:02 PM
Ladenburg Thalmann Financial Services Analysts Give Urogen Pharma (URGN) a $65.00 Price TargetLadenburg Thalmann Financial Services Analysts Give Urogen Pharma (URGN) a $65.00 Price Target
www.americanbankingnews.com - March 16 at 8:20 PM
Oppenheimer Reiterates "$62.00" Price Target for Urogen Pharma (URGN)Oppenheimer Reiterates "$62.00" Price Target for Urogen Pharma (URGN)
www.americanbankingnews.com - March 15 at 7:06 PM
UroGen Reports Fourth Quarter and Full Year 2017 Financial ResultsUroGen Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 15 at 4:54 PM
Urogen Pharma (URGN) Releases Quarterly  Earnings Results, Misses Expectations By $0.09 EPSUrogen Pharma (URGN) Releases Quarterly Earnings Results, Misses Expectations By $0.09 EPS
www.americanbankingnews.com - March 15 at 2:24 PM
Urogen Pharma (URGN) Set to Announce Earnings on ThursdayUrogen Pharma (URGN) Set to Announce Earnings on Thursday
www.americanbankingnews.com - March 9 at 11:48 PM
UroGen to Present at March 2018 Investor ConferencesUroGen to Present at March 2018 Investor Conferences
finance.yahoo.com - March 7 at 9:38 AM
Spark Investment Management LLC Grows Position in Urogen Pharma Ltd (URGN)Spark Investment Management LLC Grows Position in Urogen Pharma Ltd (URGN)
www.americanbankingnews.com - March 1 at 6:50 PM
Zacks: Brokerages Anticipate Urogen Pharma Ltd (URGN) to Announce -$0.66 Earnings Per ShareZacks: Brokerages Anticipate Urogen Pharma Ltd (URGN) to Announce -$0.66 Earnings Per Share
www.americanbankingnews.com - February 23 at 2:20 PM
Research Analysts Set Expectations for Urogen Pharma Ltds Q4 2017 Earnings (URGN)Research Analysts Set Expectations for Urogen Pharma Ltd's Q4 2017 Earnings (URGN)
www.americanbankingnews.com - February 15 at 8:02 AM
Urogen Pharma (URGN) and Tyme Technologies (TYME) Head to Head ReviewUrogen Pharma (URGN) and Tyme Technologies (TYME) Head to Head Review
www.americanbankingnews.com - February 14 at 9:08 PM
Research Analysts Issue Forecasts for Urogen Pharma Ltds FY2022 Earnings (URGN)Research Analysts Issue Forecasts for Urogen Pharma Ltd's FY2022 Earnings (URGN)
www.americanbankingnews.com - February 14 at 4:12 PM
UroGen Pharma Strengthens Management Team with the Appointment of Stephen Mullennix as Chief Operating OfficerUroGen Pharma Strengthens Management Team with the Appointment of Stephen Mullennix as Chief Operating Officer
finance.yahoo.com - February 14 at 9:08 AM
Zacks: Brokerages Anticipate Urogen Pharma Ltd (URGN) to Announce -$0.68 Earnings Per ShareZacks: Brokerages Anticipate Urogen Pharma Ltd (URGN) to Announce -$0.68 Earnings Per Share
www.americanbankingnews.com - February 6 at 12:36 PM
Urogen Pharma Ltd (URGN) Given Average Recommendation of "Buy" by AnalystsUrogen Pharma Ltd (URGN) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - January 29 at 3:30 AM

SEC Filings

UroGen Pharma (NASDAQ:URGN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

UroGen Pharma (NASDAQ:URGN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

UroGen Pharma (NASDAQ URGN) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.